Scandion Oncology Past Earnings Performance
Past criteria checks 0/6
Scandion Oncology's earnings have been declining at an average annual rate of -36.6%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-36.6%
Earnings growth rate
-13.9%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -126.0% |
| Net Margin | n/a |
| Next Earnings Update | 22 May 2024 |
Recent past performance updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06
Revenue & Expenses BreakdownBeta
How Scandion Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -39 | 14 | 32 |
| 30 Sep 23 | 0 | -44 | 11 | 41 |
| 30 Jun 23 | 0 | -59 | 16 | 49 |
| 31 Mar 23 | 0 | -73 | 17 | 61 |
| 31 Dec 22 | 0 | -77 | 17 | 65 |
| 30 Sep 22 | 0 | -76 | 13 | 67 |
| 30 Jun 22 | 0 | -66 | 12 | 60 |
| 31 Mar 22 | 0 | -56 | 10 | 53 |
| 31 Dec 21 | 0 | -52 | 8 | 48 |
| 30 Sep 21 | 0 | -43 | -3 | 55 |
| 30 Jun 21 | 0 | -31 | -1 | 42 |
| 31 Mar 21 | 0 | -22 | 1 | 30 |
| 31 Dec 20 | 0 | -17 | 3 | 22 |
| 30 Sep 20 | 0 | -11 | 27 | 0 |
| 30 Jun 20 | 0 | -14 | 23 | 0 |
| 31 Mar 20 | 0 | -14 | 19 | 0 |
| 31 Dec 19 | 0 | -12 | 16 | 0 |
| 30 Sep 19 | 0 | -17 | 5 | 0 |
| 30 Jun 19 | 0 | -12 | 4 | 0 |
| 31 Mar 19 | 0 | -10 | 3 | 0 |
| 31 Dec 18 | 0 | -8 | 3 | 0 |
| 30 Sep 18 | 0 | -4 | 1 | 0 |
Quality Earnings: SCOL is currently unprofitable.
Growing Profit Margin: SCOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCOL is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.
Accelerating Growth: Unable to compare SCOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: SCOL has a negative Return on Equity (-125.97%), as it is currently unprofitable.